Drug Trial Radar · NCT04956692
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
531
Actual
Start
Aug 5, 2021
Primary completion
Apr 4, 2023
Study completion Aug 24, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state. Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment.
Conditions
- Non-Small Cell Lung Cancer
Interventions
Pembrolizumab SCBiological
SC injection
Pembrolizumab IVBiological
IV injection
PaclitaxelDrug
IV injection
Nab-PaclitaxelDrug
IV infusion
CarboplatinDrug
IV infusion
CisplatinDrug
IV infusion
PemetrexedDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of PembrolizumabTime frame: Cycle 1: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.
- Cycle 6 Model-Based Minimal Concentration (Ctrough) of PembrolizumabTime frame: Cycle 6: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.
Locations
126 sites in 16 countries. Site status is shown where the registry gives one.
St. Bernards Medical Center ( Site 0103)
Jonesboro, Arkansas
St Joseph Heritage Healthcare-Oncology ( Site 0102)
Fullerton, California
Cancer Blood and Specialty Clinic ( Site 0105)
Los Alamitos, California
PIH Health Hematology Medical Oncology ( Site 0106)
Whittier, California
Holy Cross Hospital ( Site 0017)
Fort Lauderdale, Florida
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0104)
Hollywood, Florida
Advent Health ( Site 0013)
Orlando, Florida
Fort Wayne Medical Oncology and Hematology ( Site 0101)
Fort Wayne, Indiana
Baptist Health Lexington ( Site 0099)
Lexington, Kentucky
St Luke's Hospital - Kansas City ( Site 0033)
Kansas City, Missouri
St. Vincent Frontier Cancer Center ( Site 0058)
Billings, Montana
Montefiore Medical Center [Bronx, NY] ( Site 0040)
The Bronx, New York
The University of Tennessee Medical Center ( Site 0050)
Knoxville, Tennessee
Tennessee Oncology ( Site 0051)
Nashville, Tennessee
Oncology Consultants, PA ( Site 0052)
Houston, Texas
Millennium Physicians - Oncology ( Site 0097)
Houston, Texas
Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 0100)
Blacksburg, Virginia
West Virginia University ( Site 0056)
Morgantown, West Virginia
HOSPITAL EVANGÉLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307)
Cachoeiro de Itapemirim, Espírito Santo, Brazil
Hospital Sao Vicente de Paulo ( Site 0311)
Passo Fundo, Rio Grande do Sul, Brazil
Instituto Joinvilense de Hematologia e Oncologia ( Site 0308)
Joinville, Santa Catarina, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305)
São José do Rio Preto, São Paulo, Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0304)
São Paulo, São Paulo, Brazil
Hopital Cochin ( Site 1002)
Paris, France
Nouvel Hôpital Civil (NHC) ( Site 1018)
Strasbourg, Bas-Rhin, France
CHU Limoges CHU Dupuytren ( Site 1011)
Limoges, Haute-Vienne, France
Hôpital Foch ( Site 1019)
Suresnes, Hauts-de-Seine, France
Institut Regional du Cancer de Montpellier - ICM ( Site 1003)
Montpellier, Herault, France
Centre Hospitalier Sud Réunion ( Site 1020)
Saint-Pierre, La Reunion, France
Hopital Guillaume & Rene Laennec ( Site 1007)
Saint-Herblain, Loire-Atlantique, France
Centre Hospitalier de Pau ( Site 1016)
Pau, Pyrenees-Atlantiques, France
CHU de Rouen ( Site 1013)
Rouen, Seine-Maritime, France
Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602)
Guatemala City, Guatemala
Clinica Privada Dr. Rixci Ramirez ( Site 0601)
Guatemala City, Guatemala
INTERVASC ( Site 0605)
Guatemala City, Guatemala
Grupo Angeles SA ( Site 0604)
Guatemala City, Guatemala
Centro Regional de Sub Especialidades Médicas SA ( Site 0600)
Quetzaltenango, Guatemala
Semmelweis University-Pulmonológiai Klinika ( Site 1114)
Budapest, Hungary
Orszagos Koranyi Pulmonologiai Intezet ( Site 1104)
Budapest, Hungary
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106)
Kecskemét, Bács-Kiskun county, Hungary
Showing 40 of 126 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.